The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 May 8

PMID 25950430

Citations 18

Authors

Qin Wang

Zhenlian Wang

Linyang Chu

Xu Li

Pengcheng Kan

Xin Xin

Yu Zhu

Ping Yang

Affiliations

Soon will be listed here.

Abstract

Chemotherapy resistance is one of the major obstacles to effective glioma therapy. Currently, the mechanism underlying chemotherapy resistance is unclear. A recent study showed that miR-106a is an important molecule involved in chemotherapy resistance. To explore the effects and mechanisms of miR-106a on multidrug resistance reversal in human glioma cells, we silenced miR-106a expression in the cisplatin-resistant U87 (U87/DDP) and the gefitinib-resistant U251 (U251/G) glioma cell lines and measured the resulting drug sensitivity, cell apoptosis rate and rhodamine 123 content. In addition, we detected decreased expression of P-glycoprotein, MDR1, MRP1, GST-π, CDX2, ERCC1, RhoE, Bcl-2, Survivin and Topo-II, as well as reduced production of IL-6, IL-8 and TGF-β in these cell lines. Furthermore, we found decreased expression of p-AKT and transcriptional activation of NF-κB, Twist, AP-1 and Snail in these cell lines. These results suggest that miR-106a is a promising therapeutic target for the treatment of human multidrug resistant glioma.

Citing Articles

Overview of miR-106a Regulatory Roles: from Cancer to Aging.

Daneshpour M, Ghadimi-Daresajini A Bioengineering (Basel). 2023; 10(8).

PMID: 37627777 PMC: 10451182. DOI: 10.3390/bioengineering10080892.

Zinc Finger E-Box Binding Homeobox Family: Non-Coding RNA and Epigenetic Regulation in Gliomas.

Lenda B, Zebrowska-Nawrocka M, Turek G, Balcerczak E Biomedicines. 2023; 11(5).

PMID: 37239035 PMC: 10216372. DOI: 10.3390/biomedicines11051364.

Exosome-based strategies for diagnosis and therapy of glioma cancer.

Karami Fath M, Azami J, Masoudi A, Mosaddeghi Heris R, Rahmani E, Alavi F Cancer Cell Int. 2022; 22(1):262.

PMID: 35989351 PMC: 9394011. DOI: 10.1186/s12935-022-02642-7.

The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma.

Lu E, Gareev I, Yuan C, Liang Y, Sun J, Chen X Curr Pharm Des. 2022; 28(23):1863-1869.

PMID: 35674307 PMC: 10556399. DOI: 10.2174/1381612828666220607105746.

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).

Zeng Z, Chen Y, Geng X, Zhang Y, Wen X, Yan Q Int J Oncol. 2022; 60(6).

PMID: 35506469 PMC: 9083885. DOI: 10.3892/ijo.2022.5366.

References

Yang G, Zhang R, Chen X, Mu Y, Ai J, Shi C . MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. J Mol Med (Berl). 2011; 89(10):1037-50. DOI: 10.1007/s00109-011-0775-x. View

Kasinski A, Slack F . miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res. 2012; 72(21):5576-87. PMC: 3488137. DOI: 10.1158/0008-5472.CAN-12-2001. View

Keppler D . Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol. 2010; (201):299-323. DOI: 10.1007/978-3-642-14541-4_8. View

Huh J, Kim T, Kim K, Song J, Jung Y, Jeong J . Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer. 2013; 109(2):452-61. PMC: 3721386. DOI: 10.1038/bjc.2013.305. View

Catela Ivkovic T, Aralica G, Cacev T, Loncar B, Kapitanovic S . miR-106a overexpression and pRB downregulation in sporadic colorectal cancer. Exp Mol Pathol. 2012; 94(1):148-54. DOI: 10.1016/j.yexmp.2012.11.002. View

Conseil G, Deeley R, Cole S . Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics. 2005; 15(8):523-33. DOI: 10.1097/01.fpc.0000167333.38528.ec. View

Cohen A, Colman H . Glioma biology and molecular markers. Cancer Treat Res. 2014; 163:15-30. DOI: 10.1007/978-3-319-12048-5_2. View

Wang X, Zhang H, Wang D, Li X . Association of genetic polymorphisms of EGFR with glioma in a Chinese population. Genet Test Mol Biomarkers. 2014; 19(1):59-62. PMC: 4278171. DOI: 10.1089/gtmb.2014.0228. View

Tartarone A, Lazzari C, Lerose R, Conteduca V, Improta G, Zupa A . Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer. 2013; 81(3):328-336. DOI: 10.1016/j.lungcan.2013.05.020. View

10.

Hu Y, Gao H, Vo C, Ke C, Pan F, Yu L . Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis. Oncoscience. 2015; 1(3):205-15. PMC: 4278290. DOI: 10.18632/oncoscience.24. View

11.

Song Z, Yu X, He C, Zhang B, Zhang Y . Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer. J Thorac Dis. 2013; 5(4):400-5. PMC: 3755689. DOI: 10.3978/j.issn.2072-1439.2013.07.28. View

12.

Li K, Lu Y, Liang J, Luo G, Ren G, Wang X . RhoE enhances multidrug resistance of gastric cancer cells by suppressing Bax. Biochem Biophys Res Commun. 2008; 379(2):212-6. DOI: 10.1016/j.bbrc.2008.12.044. View

13.

Draheim V, Reichel A, Weitschies W, Moenning U . N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. Eur J Pharm Sci. 2010; 41(2):201-9. DOI: 10.1016/j.ejps.2010.06.005. View

14.

Zhu Y, Liu X, Yang P, Zhao M, Lv L, Zhang G . Alkylglyceronephosphate synthase (AGPS) alters lipid signaling pathways and supports chemotherapy resistance of glioma and hepatic carcinoma cell lines. Asian Pac J Cancer Prev. 2014; 15(7):3219-26. DOI: 10.7314/apjcp.2014.15.7.3219. View

15.

Bovell L, Shanmugam C, Putcha B, Katkoori V, Zhang B, Bae S . The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res. 2013; 19(14):3955-65. PMC: 3746330. DOI: 10.1158/1078-0432.CCR-12-3302. View

16.

Jiang X, Li N . Induction of MiR-17-3p and MiR-106a [corrected] by TNFα and LPS. Cell Biochem Funct. 2011; 29(2):164-70. DOI: 10.1002/cbf.1728. View

17.

Feng B, Dong T, Wang L, Zhou H, Zhao H, Dong F . Colorectal cancer migration and invasion initiated by microRNA-106a. PLoS One. 2012; 7(8):e43452. PMC: 3422256. DOI: 10.1371/journal.pone.0043452. View

18.

Takakura Y, Hinoi T, Oue N, Sasada T, Kawaguchi Y, Okajima M . CDX2 regulates multidrug resistance 1 gene expression in malignant intestinal epithelium. Cancer Res. 2010; 70(17):6767-78. PMC: 3153948. DOI: 10.1158/0008-5472.CAN-09-4701. View

19.

Qian C, Li P, Yan W, Shi L, Zhang J, Wang Y . Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl‑2 pathway. Mol Med Rep. 2014; 11(3):1951-5. DOI: 10.3892/mmr.2014.2951. View

20.

Besse B, Olaussen K, Soria J . ERCC1 and RRM1: ready for prime time?. J Clin Oncol. 2013; 31(8):1050-60. DOI: 10.1200/JCO.2012.43.0900. View